Cargando…

The management impact of (68)gallium-tris(hydroxypyridinone) prostate-specific membrane antigen ((68)Ga-THP-PSMA) PET-CT imaging for high-risk and biochemically recurrent prostate cancer

PURPOSE: To determine the impact on clinical management of patients with high-risk (HR) prostate cancer at diagnosis and patients with biochemical recurrence (BCR) using a new kit form of (68)Ga-prostate-specific membrane antigen (PSMA), namely tris(hydroxypyridinone) (THP)-PSMA, with positron emiss...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kulkarni, Meghana, Hughes, Simon, Mallia, Andrew, Gibson, Victoria, Young, Jennifer, Aggarwal, Ajay, Morris, Stephen, Challacombe, Ben, Popert, Rick, Brown, Christian, Cathcart, Paul, Dasgupta, Prokar, Warbey, Victoria S., Cook, Gary J. R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005085/ https://www.ncbi.nlm.nih.gov/pubmed/31872280 http://dx.doi.org/10.1007/s00259-019-04643-7

Ejemplares similares

Simple, mild, one-step labelling of proteins with gallium-68 using a tris(hydroxypyridinone) bifunctional chelator: a (68)Ga-THP-scFv targeting the prostate-specific membrane antigen
por: Nawaz, Saima, et al.
Publicado: (2017)

Targeting integrin αvβ6 with gallium-68 tris (hydroxypyridinone) based PET probes
por: Floresta, Giuseppe, et al.
Publicado: (2022)

Diagnostic Impact of Dual-Time PET/CT with (68)Gallium-PSMA in Prostate Cancer and (68)Gallium-DOTATOC in Neuroendocrine Tumors
por: Librizzi, Damiano, et al.
Publicado: (2023)

Hydroxypyridinone Chelators: From Iron Scavenging to Radiopharmaceuticals for PET Imaging with Gallium-68
por: Cusnir, Ruslan, et al.
Publicado: (2017)

Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer
por: Lenzo, Nat P., et al.
Publicado: (2018)

Clinical Utility of Gallium-68 PSMA PET/CT Scan for Prostate Cancer
por: Kallur, Kumaraswamy G, et al.
Publicado: (2017)

Tuning the properties of tris(hydroxypyridinone) ligands: efficient (68)Ga chelators for PET imaging
por: Imberti, Cinzia, et al.
Publicado: (2019)

Manipulating the In Vivo Behaviour of (68)Ga with Tris(Hydroxypyridinone) Chelators: Pretargeting and Blood Clearance
por: Imberti, Cinzia, et al.
Publicado: (2020)

Targeted Prostate Biopsy Using (68)Gallium PSMA-PET/CT for Image Guidance
por: Simopoulos, Demetrios N., et al.
Publicado: (2017)

Gallium-68 prostate-specific membrane antigen ([(68)Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study
por: Lawhn-Heath, Courtney, et al.
Publicado: (2020)

Enhancing PET Signal at Target Tissue in Vivo: Dendritic and Multimeric Tris(hydroxypyridinone) Conjugates for Molecular Imaging of α(v)β(3) Integrin Expression with Gallium-68
por: Imberti, Cinzia, et al.
Publicado: (2016)

Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
por: Meyer, Catherine, et al.
Publicado: (2022)

Pitfalls in Gallium-68 PSMA PET/CT Interpretation—A Pictorial Review
por: Shetty, Deepa, et al.
Publicado: (2018)

Optimization of Automated Radiosynthesis of Gallium-68-Labeled PSMA11 with Two [(68)Ge]Ge/[(68)Ga]Ga Generators: Fractional Elution or Prepurification?
por: Durieux, Flore, et al.
Publicado: (2023)

Diagnostic performance of (68)Gallium-PSMA-11 PET/CT to detect significant prostate cancer and comparison with (18)FEC PET/CT
por: Hoffmann, Manuela A., et al.
Publicado: (2017)

Distribution of prostate cancer recurrences on gallium‐68 prostate‐specific membrane antigen ((68)Ga‐PSMA) positron‐emission/computed tomography after radical prostatectomy with pathological node‐positive extended lymph node dissection
por: Huits, Thijs H., et al.
Publicado: (2020)

Clinical outcomes of anterior prostate cancers treated with robotic assisted radical prostatectomy
por: Saghir, Reyan, et al.
Publicado: (2022)

Guy’s and St Thomas NHS Foundation active surveillance prostate cancer cohort: a characterisation of a prostate cancer active surveillance database
por: Shah, Salonee, et al.
Publicado: (2021)

[(68)Ga]Ga-PSMA-11: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
por: Hennrich, Ute, et al.
Publicado: (2021)

Correction to: Guy’s and St Thomas NHS Foundation active surveillance prostate cancer cohort: a characterisation of a prostate cancer active surveillance database
por: Shah, Salonee, et al.
Publicado: (2022)

(68)Gallium-labelled PSMA-PET/CT as a diagnostic and clinical decision-making tool in Asian prostate cancer patients following prostatectomy
por: Tan, Janice S.H., et al.
Publicado: (2019)

The positivity rate of 68Gallium-PSMA-11 ligand PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer
por: Hoffmann, Manuela A., et al.
Publicado: (2019)

Specificity of (68)Ga-PSMA PET/CT for Prostate Cancer - Myths and Reality
por: Sasikumar, Arun
Publicado: (2017)

Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET
por: Notni, Johannes, et al.
Publicado: (2012)

In Vivo Trafficking of the Anticancer Drug Tris(8-Quinolinolato) Gallium (III) (KP46) by Gallium-68/67 PET/SPECT Imaging
por: Darwesh, Afnan M. F., et al.
Publicado: (2023)

Pilot study: use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour
por: Rhee, Handoo, et al.
Publicado: (2016)

Meningioma uptake of (68)Gallium-PSMA-11 as a pitfall on positron emission tomography/computer tomography
por: Courtney, Michael, et al.
Publicado: (2021)

Multi-curie production of gallium-68 on a biomedical cyclotron and automated radiolabelling of PSMA-11 and DOTATATE
por: Thisgaard, Helge, et al.
Publicado: (2021)

Radiation dosimetry of [(68)Ga]PSMA-11 in low-risk prostate cancer patients
por: Sandgren, Kristina, et al.
Publicado: (2019)

(68)Ga-PSMA-PET/CT for the evaluation of liver metastases in patients with prostate cancer
por: Damjanovic, Jonathan, et al.
Publicado: (2019)

Re: The role of (68)Ga-PSMA-PET/CT in radiotherapy planning in prostate cancer
por: Cihan, Yasemin Benderli
Publicado: (2019)

Performance of Ga-68 PSMA PET/CT for diagnosis and grading of local prostate cancer
por: Kwan, Timothy N., et al.
Publicado: (2021)

(68)Ga-PSMA PET-CT and PSMA score affecting therapeutic decision-making in high-risk prostatic carcinoma
por: Yasmin, Tahira, et al.
Publicado: (2023)

Cyclotron Production of Gallium-68 Radiopharmaceuticals Using the (68)Zn(p,n)(68)Ga Reaction and Their Regulatory Aspects
por: Ashhar, Zarif, et al.
Publicado: (2022)

New Tris(hydroxypyridinone) Bifunctional Chelators Containing Isothiocyanate Groups Provide a Versatile Platform for Rapid One-Step Labeling and PET Imaging with (68)Ga(3+)
por: Ma, Michelle T., et al.
Publicado: (2015)

(68)Ga-PSMA-11 PET/CT versus (68)Ga-PSMA-11 PET/MRI for the detection of biochemically recurrent prostate cancer: a systematic review and meta-analysis
por: Huang, Ruizhe, et al.
Publicado: (2023)

Diagnostic Challenges in Prostate Cancer and (68)Ga-PSMA PET Imaging: A Game Changer?
por: Zaman, Maseeh uz, et al.
Publicado: (2017)

(68)Ga-PSMA-PET/CT for the evaluation of pulmonary metastases and opacities in patients with prostate cancer
por: Damjanovic, Jonathan, et al.
Publicado: (2018)

68Ga-PSMA PET/CT imaging in recurrent prostate cancer: Where are we now?
por: Witkowska-Patena, Ewa, et al.
Publicado: (2017)

(68)Ga-PSMA Cerenkov luminescence imaging in primary prostate cancer: first-in-man series
por: olde Heuvel, Judith, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kn59s9c4vr9bsnm501ern3ac9h